Hyphens Pharma has secured exclusive rights from Japan-based Maruho to register and commercialise the shingles treatment Amenalief ® Tab 200 mg across 10 ASEAN countries, addressing a high prevalence of varicella-zoster virus among older adults.
- Product scope: Amenalief® Tab 200 mg targets varicella-zoster virus via helicase-primase inhibition; once-daily regimen.
- Regional rollout: Rights cover Singapore and nine other ASEAN markets.
- Clinical context: High percentage of adults over 50 carry the virus, posing shingles risk.
This summary is based on reporting by Singapore Business Review.
